



Dynex Technologies Acquired By Telegraph Hill Partners

Gains additional resources to support growth and innovation

Dynex Technologies (Dynex) has been acquired by Telegraph Hill Partners (THP), a leading venture capital and growth equity firm dedicated to the life science and healthcare industries. THP will infuse Dynex with significant resources and capital, enabling the company to expand its operations, improve manufacturing capacity and grow its client services organization.

“We are proud of our 60-year history of delivering best in class products with an ongoing commitment to innovation. With THP’s additional resources, we look forward to continuing to execute on our strategy for future growth,” stated Adrian Bunce, President of Dynex Technologies.

Concurrent with the transaction, John Lillig will join the Dynex Board of Directors as Executive Chairman. John brings a successful track record of developing and building leading, innovative life science and clinical diagnostics companies such as NEXUS Biosystems and Agena Bioscience. John Lillig commented, “Dynex Technologies has created a strong position in the area of ELISA based automated instrumentation for the clinical diagnostics market. I am excited to begin working with the Dynex team on their initiatives for the future growth of the current business and the development of new products and innovative solutions.”

About Dynex Technologies (www.dynex.com): Dynex pioneered microplate technology more than 60 years ago, and has since delivered a series of cutting edge, best-in-class ELISA processing systems, including the 4-plate DSX, 2-plate DS2 and Agility high throughput systems. Dynex designs each of its products to meet the rigorous demands of the clinical laboratory. Based in Chantilly, Virginia, USA, with offices in Hong Kong, Germany and the U.K. Dynex is committed to delivering innovative laboratory products to meet the ever-changing needs of the customers we serve.

About THP (www.telegraphhillpartners.com): Telegraph Hill Partners, founded in 2001 and based in San Francisco and San Diego, CA, invests in commercial stage life science, medical technology and healthcare companies.

